Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Duvelisib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Duvelisib. Displaying page 1 of 1.
    EudraCT Number: 2016-000848-34 Sponsor Protocol Number: IPl-145-23 Start Date*: 2016-09-21
    Sponsor Name:Verastem, INC
    Full Title: Long term, Continued Treatment and Follow up Study in Subjects with Hematologic Malignancies Treated with Duvelisib (IPI 145)
    Medical condition: Hematologic Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001123-13 Sponsor Protocol Number: VS-0145-225 Start Date*: 2019-12-02
    Sponsor Name:Secura Bio, Inc
    Full Title: A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
    Medical condition: Peripheral T-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001381-14 Sponsor Protocol Number: VS-0145-229 Start Date*: 2019-10-31
    Sponsor Name:Verastem, Inc.
    Full Title: A Phase 2, Randomized, Open-label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non-Hodgkin Lymphoma (iNHL)
    Medical condition: Indolent Non-Hodgkin Lymphoma (iNHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004033-28 Sponsor Protocol Number: IPI-145-22 Start Date*: 2016-05-04
    Sponsor Name:Infinity Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects...
    Medical condition: Indolent Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) EE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003639-31 Sponsor Protocol Number: IPI-145-12 Start Date*: 2014-11-06
    Sponsor Name:Infinity Pharmaceuticals, Inc
    Full Title: A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07
    Medical condition: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) HU (Completed) ES (Completed) GB (Completed) BE (Completed) AT (Completed) DE (Completed) FR (Completed) LV (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002405-61 Sponsor Protocol Number: IPI-145-07 Start Date*: 2014-02-20
    Sponsor Name:Infinity Pharmaceuticals, Inc
    Full Title: A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Medical condition: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Completed) IT (Completed) GB (Completed) BE (Completed) AT (Completed) DE (Completed) LV (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004729-15 Sponsor Protocol Number: IPI-145-21 Start Date*: 2016-05-27
    Sponsor Name:Infinity Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized Study of Duvelisib Administered in Combination with Rituximab vs R-CHOP in Subjects with Relapsed/Refractory Follicular Lymphoma
    Medical condition: Relapsed/Refractory Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10029473 Nodular (follicular) lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005459-13 Sponsor Protocol Number: IPI-145-19 Start Date*: 2015-09-15
    Sponsor Name:Infinity Pharmaceuticals, Inc.
    Full Title: A Two-arm, Phase 1b/2 Study of IPI-145 Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10025311 Lymphoma (non-Hodgkin's) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) ES (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002406-31 Sponsor Protocol Number: IPI-145-08 Start Date*: 2014-09-16
    Sponsor Name:Infinity Pharmaceuticals, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of IPI-145 in Combination with Rituximab vs Rituximab in Subjects with Previously-Treated Follicular Lymphoma
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10025311 Lymphoma (non-Hodgkin's) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Prematurely Ended) HU (Completed) ES (Completed) BE (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004008-20 Sponsor Protocol Number: IPI-145-06 Start Date*: 2014-01-13
    Sponsor Name:Verastem, Inc.
    Full Title: A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma.
    Medical condition: Refractory Indolent Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029627 Non-Hodgkin's lymphoma unspecified histology intermediate grade refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) HU (Completed) CZ (Completed) ES (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 22:03:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA